Black Swan Analysis Epiomic Epidemiology Forecast Report on Testicular Cancer in 24 Major Markets
Testicular cancer is a relatively rare cancer; although it is the most commonly diagnosed cancer in males aged 2034. There are two main types of testicular cancer; seminomas and nonseminomas, which develop from germ cells in the testicles. The standard treatment procedure involves the complete removal of the testis with the tumour.
This report provides the current incident population for testicular cancer across 24 Major Markets USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Norway, Denmark, Switzerland, Russia, Turkey, Saudi Arabia, South Africa, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina split by gender and 5year age cohort. In addition to the current incidence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a valueadded level of insight from the analysis team at Black Swan, several features of testicular cancer patients, as well as the main symptoms and comorbidities of the disease have been quantified and presented alongside the overall incidence figures. These subpopulations within the main disease are also included at a country level across the 10year forecast snapshot.
Main symptoms and comorbidities of testicular cancer include:
Presence of lump in one testis
Gynaecomastia
Pain lower back, scrotum or lower abdomen
Cryptorchidism
Hypospadias
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most uptodate information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
Ability to quantify patient populations in global testicular cancer market to target the development of future products, pricing strategies and launch plans.
Further insight into the incidence of the subdivided types of testicular cancer and identification of patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Better understanding of the impact of specific comorbid conditions on the incident population of testicular cancer patients.
Identification of testicular cancer patient subpopulations that require treatment.
Better understanding of the specific markets that have the largest number of thyroid cancer patients.
Original Article: EPIOMIC EPIDEMIOLOGY SERIES: TESTICULAR CANCER FORECAST IN 24 MAJOR MARKETS 20182028 [Report Updated: 01012018] Prices from USD $5800